Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of report (Date of earliest event reported):

March 31, 2004

 

 

Vicuron Pharmaceuticals Inc.

(Exact Name of Registrant As Specified in its Charter)

 

 

Delaware   000-31145   04-3278032

(State or Other Jurisdiction

of Incorporation)

   (Commission File Number)  

(I.R.S. Employer

Identification Number)

 

455 South Gulph Road, Suite 305, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

 

(610) 205-2300

(Registrant’s telephone number, including area code)

 

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

 

Item 7. Exhibits.

 

The exhibit listed on the Exhibit Index (following this Report’s signature page) is furnished with this Report.

 

Item 12. Results of Operations and Financial Condition.

 

On May 6, 2004, Vicuron Pharmaceuticals Inc. issued a press release regarding its financial results for the three months ended March 31, 2004. A copy of the press release announcing these financial results is attached as Exhibit 99.1.

 

The information (including the exhibit incorporated into this Item 12 by reference) shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as may be expressly set forth by specific reference in such a filing.

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    VICURON PHARMACEUTICALS INC.
                            (Registrant)
Date: May 6, 2004   By:  

/s/ GEORGE F. HORNER III

        George F. Horner III
        President and Chief Executive Officer

EXHIBIT INDEX

 

Pursuant to Item 601(a)(2) of Regulation S-K, this exhibit index immediately precedes the exhibit.

 

Exhibit No.
  

Description

99.1   Press release of Vicuron Pharmaceuticals Inc. dated May 6, 2004, reporting its financial results for the three months ended March 31, 2004.